We wish to congratulate the Takeda oveporexton team on positive results from their pivotal phase III program in narcolepsy type 1. We are so pleased these data indicate that treatment with oveporexton in adults with NT1 resulted in substantial benefit across multiple symptoms of the disorder, including the ability to maintain attention. This milestone underscores the potential of oveporexton to improve the lives of people with NT1.
We are pleased to share results from our FirstLight and RadiantLight global Phase 3 studies for an investigational treatment for people with #narcolepsy type 1 (NT1). NT1 is a rare, chronic neurological disorder that is caused by low levels of orexin neurons in the brain, leading to a disrupted sleep-wake cycle among other symptoms. Read more here: https://lnkd.in/eizbwEM7 For Media and Investors only.
